Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD

被引:0
作者
Gerald Holtmann
Marc-André Bigard
Peter Malfertheiner
Roy Pounder
机构
[1] University of Adelaide,Department of Gastroenterology and Hepatology, Princess Alexandra Hospital
[2] Hôpital de Brabois—rue du Morvan,Service d’Hépatogastroentérologie
[3] Otto-von-Guericke University Magdeburg,Department of Gastroenterology, Hepatology and Infectious Diseases
[4] University of London,Department of Medicine
来源
International Journal of Clinical Pharmacy | 2011年 / 33卷
关键词
Gastroesophageal reflux disease; GERD; Guidance; Omeprazole; OTC drugs; Pharmacist; Proton pump inhibitors;
D O I
暂无
中图分类号
学科分类号
摘要
Objective The aim of this paper was to develop a guideline on the over-the-counter management of gastroesophageal reflux disease with proton pump inhibitors (i.e. omeprazole). Setting A meeting of internationally renowned gastroenterologists in January 2009, in Berlin, Germany. Methods An expert panel group of gastroenterologists convened to develop a consensus-based algorithm for pharmacists for over-the-counter (OTC) treatment with proton pump inhibitors (PPIs). Key considerations were the short-term safety and efficacy of PPIs, and the extent of the risk to the sufferer, owing to the treatment not being controlled by a physician. Main outcome measures A consensus-based treatment algorithm for the OTC management of gastroesophageal reflux disease and evidence-based guidance on the use of OTC PPIs. Results As defined by the treatment algorithm, the pharmacist should first confirm the diagnosis based on the presence of typical symptoms and secondly, as a result, rule out general practitioner referral. The third step focuses on the nature, severity and frequency of the symptoms—the patients who might have the highest benefit from a short course (14 days) of OTC PPIs are those with less than three episodes of heartburn and/or acid regurgitation per week. Patients who have three or more episodes per week can use the OTC PPIs but should also be encouraged to visit a physician, and those who already have a diagnostic work-up can use proton pump inhibitors as rescue treatment if they are known responders. Guidance for pharmacists, in the form of questions and answers, summarises the current published clinical experience with PPIs in terms of their efficacy and safety, and optimal treatment schedule. Conclusions Gastroesophageal reflux disease imposes a considerable burden on sufferers. Owing to their accepted efficacy and safety, PPIs are becoming popular as OTC options for the treatment of gastroesophageal reflux disease symptoms such as heartburn and acid regurgitation. Effective self-management of gastroesophageal reflux disease with OTC PPIs, e.g. omeprazole, could lead to lasting freedom from symptoms and improved quality of life for sufferers.
引用
收藏
页码:493 / 500
页数:7
相关论文
共 309 条
[41]  
Jacobson BC(2003)Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors Aliment Pharmacol Ther 17 1507-1140
[42]  
Somers SC(2005)Heartburn-dominant, uninvestigated dyspepsia: a comparison of ‘PPI-start’ and ‘H2-RA-start’ management strategies in primary care–the CADET-HR Study Aliment Pharmacol Ther 21 1189-255
[43]  
Fuchs CS(2006)Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment Scand J Gastroenterol 41 1132-291
[44]  
Kelly CP(2008)Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients Aliment Pharmacol Ther 28 250-808
[45]  
Camargo CA(1998)Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease Dig Dis 16 284-563
[46]  
El-Serag H(1999)Pantoprazole: a new proton pump inhibitor in the management of upper gastrointestinal disease Drugs Today (Barc) 35 773-215
[47]  
Hill C(2005)Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials Clin Gastroenterol Hepatol 3 553-979
[48]  
Jones R(2005)Treatment of reflux disease with proton pump inhibitors Pharm Unserer Zeit 34 210-275
[49]  
Jones R(1997)Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response Scand J Gastroenterol 32 974-1598
[50]  
Armstrong D(2008)Healthcare seeking in gastro-oesophageal reflux disease: a qualitative study Eur J Gastroenterol Hepatol 20 269-833